Clifford StocksFounder

United States - Seattle, Washington

Clifford J. Stocks is the Founder and Chief Executive Officer of OncoResponse, Inc., which was formed as a broad strategic alliance between Theraclone Sciences and MD Anderson Cancer Center, focused on immuno-oncology and the treatment of cancer. From December 2011 until the founding of OncoResponse, he was the Chief Executive Officer of Theraclone Sciences, Inc. in Seattle Washington, a therapeutic antibody company focused on the treatment of infectious disease. Previously he helped form and served as Chief Business Officer of Calistoga Pharmaceuticals, Inc. who developed the PI3K inhibitor, idelalisib, approved in 2013 as ZydeligTM to treat hematological malignancies. At Calistoga he led the partnering and M&A processes, activities and teamwork that resulted in the acquisition of Calistoga in 2011 by Gilead for $600 million. Mr. Stocks brings more than thirty years of experience in the biotech industry, including business and corporate development, strategy and business practices. His career includes 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and he was a key architect of the Lilly ICOS joint venture partnership leading to their $2.3 billion merger in 2007. Previously in his career, Mr. Stocks was a management consultant in the Health Services practice of Booz, Allen & Hamilton, and his early career includes academic research on staff in the department of immunology at the University of Utah and on staff in the department of molecular genetics and cell biology at the University of Chicago, where he also received an MBA degree from the University of Chicago Booth Graduate School of Business.

Specialties: Collaboration formation and teambuilding, deal-making and negotiations, technology evaluation and valuation, and new company and capital formation